

Annex 1



Ms Angelene Chan
Chairman
DP Architects

Ms Angelene Chan is the Chairperson of DP Architects (DP), an influential architecture practice with 900 employees and 18 offices worldwide.

As an architect, she sees the practice of architecture as a deeply meaningful act that has the power to bring communities together and improve lives. Tapping into her innate ability to balance practical requirements of a brief and invigorating the local context in her designs, Ms Chan has built an impressive portfolio of works showcasing authentic and purposeful architecture that fulfils the needs of the users and community. She received recognition for her design verve in 2010 when she was listed as one of Singapore's 20 leading architects under the age of 45 by the Urban Redevelopment Authority (URA).

In 2015, she was conferred the President's Design Award (P*DA) for her design of Sunray Woodcraft Construction Headquarters, and in 2018, she was named P*DA Designer of the Year by President Halimah Yacob, Singapore's highest design accolade. Among her portfolio of works are notable projects that have placed both DPA and Singapore on the map. These include The Dubai Mall, Resorts World Sentosa, the transformation of Wisma Atria shopping mall along Singapore's famed Orchard Road and the rejuvenation of Paya Lebar Central into a nodal business hub with Paya Lebar Quarter, a mixed-use development comprising three office towers, a retail mall and a residential development.

During her term as CEO of DP from January 2016 to January 2021, Ms Chan steered the practice in strategic growth towards greater international presence, and higher design and service delivery benchmarks through increased specialisation in architecture-related disciplines and use of technology. As Chairman, she continues in this work, ensuring that DP's strategic roadmap aligns with the growth of DP's global and specialisation offices to meet the firm's vision and goals.

An active contributor to the profession and building industry, Ms Chan sits on the URA board, the Singapore Land Authority board, the Building and Construction Authority of Singapore board and the Sentosa Development Corporation board. She chairs URA's Design Advisory Committee where she reviews, advises and promotes best practices in architecture and urban design. In recognition and appreciation of her contributions as a member of the Board of Architects, Singapore and as a member of the Professional Engineers Board, Singapore, Ms Chan was awarded the MND Medallion in 2022.

Beyond the Built Environment sector, Ms Chan serves on the Board of Trustees for World

Community of Christian Meditation, which is headquartered in London, UK. She also serves as the Vice-Chairperson of the Dover Park Hospice governing council and as the Chairperson of its Building & Development Committee. For her contributions to the community, Ms Chan was presented with the RBS Coutts & The Financial Times Women in Asia Award in 2010 and was named Her World's Woman of the Year in 2017.

Ms Chan graduated with a Bachelor of Architecture (First Class Honours) from the University of Adelaide.



Ms Donna See
CEO
Xora Innovation

Ms Donna See is the founding CEO of Xora Innovation, an early-stage deep science investing and venture building platform of Temasek. She brings to bear over 20 years of experience in the nuanced process of transforming raw scientific and engineering innovation into commercially viable ventures.

Previously, she served in start-up and founding executive roles, including Chief Business Officer of TARA Biosystems, a venture-backed cardiac precision medicine company, acquired by Flagship Pioneering's Valo Health to accelerate AI-enabled drug discovery of cardiovascular medicines; co-founder of Vixen Pharmaceuticals, a founder-led venture pursuing innovative therapies for autoimmune dermatologic conditions whose groundbreaking work in alopecia areata is now benefitting patients in the US, EU, and Japan (sold by Eli Lilly under the tradename Olumiant®, under license from Aclaris Therapeutics (NASDAQ: ACRS) which acquired Vixen); and Chief Business Officer of Allied-Bristol Life Sciences, a joint venture of Allied Minds and Bristol-Myers Squibb (NYSE: BMS), developing therapeutic assets in heart failure, oncology, immune disorders, fibrosis, and genetically-defined disorders from leading US academic labs. Ms See also served as Vice President, Investments at Allied Minds, an LSE-listed venture building platform pursuing opportunities from US university and federal labs in the advanced materials, computing, communications, and cybersecurity domains.

Prior to Allied Minds, Ms See was Director at Columbia Technology Ventures, driving commercialisation of a portfolio of over 2,000 assets (via licensing, patent pools, patent auctions, patent assertion/litigation, as well as via student/faculty entrepreneurship), including more than 30 deep tech ventures arising from engineering and basic sciences labs at Columbia University and clinical innovations from Columbia University Medical Center. She was previously on the technology 'buy side' at New York-Presbyterian Hospital, where she was involved with the assessment of new technologies and business opportunities arising therefrom. Earlier in her career, Ms See worked on public-private healthcare initiatives with the US Centers for Disease Control, the US Public Health Service, Departments of Health (in San Francisco, New York City, and Hawaii) and international economic development agencies including the World Bank.

Ms See received her Master of Business Administration and Master of Public Health (in Health Policy) from Columbia University and holds a Bachelor of Arts in the Natural Sciences from The Johns Hopkins University.

Born in Singapore of Peranakan and Hokkien heritage, Ms See spent her childhood years in the Caribbean, North Africa, and the Mediterranean before moving to the US, where she spent most of her academic and professional career (in Baltimore, Washington DC, San Francisco, Honolulu, New York, and Boston) before returning to Singapore in 2019.



Mr Ong Chong Tee

Chairman, ACRA Board
Accounting and Corporate Regulatory Authority

Mr Ong Chong Tee was with the Monetary Authority of Singapore (MAS) from 1986 to 2021. He held senior positions in the areas of reserve management, central banking monetary operations and market development. He was most recently MAS' Deputy Managing Director of Financial Supervision, overseeing the financial sectors of banking, insurance, capital markets, payment services as well as the supervision of technology and money laundering risks from 2014 to 2021.

Mr Ong had served on numerous boards of public agencies including Singapore Land Authority, Urban Redevelopment Authority, Central Provident Fund and Housing & Development Board. As the MAS representative, he was also an advisory member of the Sim Kee Boon Institute for Financial Economics of SMU, Risk Management Institute of NUS, the EDHEC-Risk Institute and the ASEAN+3 Macroeconomic Office. Mr Ong also served as a member of MINDEF's SAVER-Premium Board of Trustee and MHA's INVEST Board of Trustee. Presently, Mr Ong serves on various boards in the public and private sectors, including as Chairman of the Accounting and Corporate Regulatory Authority. He is also a member of the GIC Risk Committee.

Mr Ong graduated with an Honours Degree in Chemical Engineering from the National University of Singapore in 1985 and attended the Advanced Management Programme of Harvard Business School. He was awarded the Public Administration Medal (Gold) in 2007 and Public Administration Medal (Gold) (Bar) in 2021 by the President of Singapore.